User Posts: admin3
0
Conference Highlights from the 2023 ASH Annual Meeting
0

This past weekend, the CURE® staff was busy covering the American Society of Hematology (ASH) Annual Meeting.ASH is the largest blood cancer conference in ...

0
Obesity May Lead to Aggressive Breast Cancer Tumor Biology
0

Biological differences may lead to aggressive tumor biology, according to data regarding racial disparities and the effect of obesity in patients with ...

0
Decline in smoking rates stalled during the pandemic
0

The decline in how many people smoke (smoking prevalence) in England has nearly ground to a halt since the start of the pandemic, according to a new ...

0
Expert Hopes to See New Drug Combinations for MPNs in 2024
0

While there have been many exciting advancements for the treatment of myeloproliferative neoplasms (MPNs) in 2023, Dr. Lucia Masarova, is hoping to see ...

0
How Holiday Conversations About Cancer Can Save Lives
0

When my Mom passed away when I was nine, her death fractured our family, making the time we spent together even more challenging. My siblings, significantly ...

0
Jaypirca, ‘Much-Needed’ Treatment for CLL and SLL, Approved by FDA
0

The recent approval by the Food and Drug Administration (FDA) of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) or small ...

0
FDA Approves Iwilfin for High-Risk Neuroblastoma in Adults and Children
0

The FDA approved Iwilfin (eflornithine) to treat adult and pediatric patients with high-risk neuroblastoma.The Food and Drug Administration (FDA) approved ...

0
Lost-Lasting Responses With Yescarta for High-Risk Large B-Cell Lymphoma
0

Durable responses were observed when Yescarta (axicabtagene ciloleucel) was used as a first-line therapy for patients with high-risk large B-cell lymphoma ...

0
FDA Prioritizes Review of Elahere in Ovarian Cancer
0

The Food and Drug Administration (FDA) has ordered a supplemental Biologics License Application (sBLA) for the approval of Elahere (mirvetuximab ...

0
Why H.M. Treasury (and all of us) can’t ignore a looming £1 billion research funding gap – Cancer Research UK
0

In over a decade working in the Civil Service, I learned that getting the Treasury to listen to why your policy area needed investment was not easy. In ...

User Deals: admin3
Browsing All Comments By: admin3
CML Alliance
Logo
Enable registration in settings - general
Compare items
  • Total (0)
Compare
0
Shopping cart